Fly News Breaks for March 4, 2020
Mar 4, 2020 | 08:17 EDT
Stifel analyst Daniel Arias said Qiagen (QGEN) has a history of "checkered execution and highly visible shortfalls," but its portfolio does contain strong established businesses and early stage assets with good potential and operating under the Thermo Fisher (TMO) umbrella should given Qiagen "a shot at maximizing potential." While he does not see Qiagen as "the game-changer that the Fisher and LIFE deals were overall," he does view the deal as a solid transaction that adds to an already "compelling" thesis at Thermo Fisher, on which he keeps a Buy rating.
News For TMO;QGEN From the Last 2 Days
Sep 22, 2021 | 06:26 EDT
BTIG analyst Sung Ji Nam raised the firm's price target on Thermo Fisher to $700 from $610 and keeps a Buy rating on the shares after its investor day presentation. The analyst cites the company's accelerating growth potential on both the top and bottom lines along with its $48B in additional capital deployment opportunity for M&A through 2025.